We Offer Worldwide Shipping
Login Wishlist

Kavain

$355

  • Brand : BIOFRON

  • Catalogue Number : BF-K4001

  • Specification : 98%(HPLC)

  • CAS number : 500-64-1

  • Formula : C14H14O3

  • Molecular Weight : 230.263

  • PUBCHEM ID : 5281565

  • Volume : 25mg

In stock

Quantity
Checkout Bulk Order?

Catalogue Number

BF-K4001

Analysis Method

HPLC,NMR,MS

Specification

98%(HPLC)

Storage

2-8°C

Molecular Weight

230.263

Appearance

Powder

Botanical Source

Piper methysticum

Structure Type

Phenylpropanoids

Category

SMILES

COC1=CC(=O)OC(C1)C=CC2=CC=CC=C2

Synonyms

(2R)-4-methoxy-2-[(E)-2-phenylethenyl]-2,3-dihydropyran-6-one

IUPAC Name

(2R)-4-methoxy-2-[(E)-2-phenylethenyl]-2,3-dihydropyran-6-one

Density

1.2±0.1 g/cm3

Solubility

DMSO : ≥ 125 mg/mL (542.86 mM)
*"≥" means soluble, but saturation unknown.

Flash Point

184.6±23.3 °C

Boiling Point

432.6±45.0 °C at 760 mmHg

Melting Point

142-148ºC

InChl

InChI=1S/C14H14O3/c1-16-13-9-12(17-14(15)10-13)8-7-11-5-3-2-4-6-11/h2-8,10,12H,9H2,1H3/b8-7+/t12-/m0/s1

InChl Key

XEAQIWGXBXCYFX-GUOLPTJISA-N

WGK Germany

RID/ADR

HS Code Reference

2932990000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:500-64-1) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

PMID

31877429

Abstract

A simple and fast bioanalytical method for the quantification of kavain in mice plasma was developed using liquid chromatography (LC)-tandem mass spectrometry (MS/MS). A full method validation was performed, according to regulatory guidelines, employing isotopically labeled kavain as the internal standard (racemic-kavain-d3). For the quantification, [M+H]+ was formed using an electrospray ionization (ESI) source in the positive ion mode and multiple reaction monitoring (MRM) was employed using a quadrupole-linear ion trap (4000 QTRAP®) instrument. The monitored MRM transitions were 231.0 → 115.1 and 231.0 → 152.8 for kavain; and 234.2 → 199.2 for the internal standard. A linear response was obtained at the concentration range of 10 to 200 ng/mL with intra- and inter-day variations within the acceptable criteria for all quality control samples. After validation, the method was successfully applied for the quantification of kavain in mice plasma after oral administration of the kavain standard and Kava-kava extract. The plasma concentration over time results were applied for a pharmacokinetics study. The obtained pharmacokinetic parameters indicated a considerably higher bioavailability for kavain when Kava-kava extract was administered due to a pharmacokinetic synergism between the analyte and the other compounds present in the extract.

KEYWORDS

Kava-kava; Kavain; LC-MS/MS; Method validation; Pharmacokinetic study.

Title

Liquid chromatography-tandem mass spectrometry bioanalytical method for the determination of kavain in mice plasma: Application to a pharmacokinetic study

Author

Juliana Veloso Ferreira 1, Alysson Vinicius Braga 1, Renes de Resende Machado 1, Deborah Michel 2, Gerson Antônio Pianetti 3, Anas El-Aneed 4, Isabela Costa Cesar 5

Publish date

2020 Jan 15

PMID

31265262

Abstract

Kavain is an active and major component in Piper methysticum Forst. (kava), which is a widely used dietary supplement for the treatment of anxiety, insomnia, and stress. However, kava-containing products can cause liver toxicity, and its underlying mechanisms are understudied. Cytochrome P450s (CYPs)-mediated bioactivation and biotransformation are highly associated with drug toxicity. In the current study, we profiled the metabolic pathways of kavain in mouse liver, urine, and feces. Overall, 28 kavain metabolites were identified including 17 new ones. The metabolic pathways of kavain include glutathione (GSH) conjugation, oxidation, dehydrogenation, O-demethylation, sulfation, and glucuronidation. The identification of kavain-GSH adducts suggests the formation of reactive metabolites of kavain in the liver. We further illustrated that CYP2C19, a highly polymorphic and inducible enzyme, was the major enzyme contributing to kavain biotransformation and bioactivation. Our data can be used to guide the safe use of kava products by preventing potential herb-drug interactions and hepatotoxicity.

Title

Enzymes and Pathways of Kavain Bioactivation and Biotransformation

Author

Pengcheng Wang 1, Junjie Zhu 1, Amina I Shehu 1, Jie Lu 1, Jing Chen 1, Xiao-Bo Zhong 2, Xiaochao Ma 1

Publish date

2019 Jul 15

PMID

30078210

Abstract

Osteoclasts are responsible for bone resorption during the process of bone remodeling. Increased osteoclast numbers and bone resorption activity are the main factors contributing to bone loss-related diseases such as osteoporosis. Therefore, modulating the formation and function of osteoclasts is critical for the effective treatment of osteolysis and osteoporosis. Kavain is the active ingredient extracted from the root of the kava plant, which possesses known anti-inflammatory properties. However, the effects of kavain on osteoclastogenesis and bone resorption remain unclear. In this study, we found that kavain inhibits receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast differentiation and fusion using tartrate-resistant acid phosphatase staining and immunofluorescence. Furthermore, kavain inhibited bone resorption performed by osteoclasts. Using reverse transcription-polymerase chain reaction and western blot analysis, we found that kavain downregulates the expression of osteoclast marker genes, such as nuclear factor of activated T cells, cytoplasmic 1 (Nfatc1), v-atpase d2 (Atp6v0d2), dendrocyte expressed seven transmembrane protein (Dcstamp), matrix metallopeptidase 9 (Mmp9), cathepsin K (Ctsk), and Acp5. Additionally, kavain repressed RANKL-induced calcium oscillations, nuclear factor of activated T cells activation, and mitogen-activated protein kinase phosphorylation, while leaving NF-κB unaffected. We found no effects of kavain on either osteoblast proliferation or differentiation. Besides, kavain inhibited bone loss in ovariectomized mice by suppressing osteoclastogenesis. Collectively, these data suggest a potential use for kavain as a candidate drug for the treatment of osteolytic diseases.

KEYWORDS

MAPK; bone resorption; calcium; kavain; osteoclast.

Title

Modulating calcium-mediated NFATc1 and mitogen-activated protein kinase deactivation underlies the inhibitory effects of kavain on osteoclastogenesis and bone resorption

Author

Qiang Guo 1 2, Zhen Cao 2 3, Bo Wu 4, Fangxiao Chen 5, Jennifer Tickner 2, Ziyi Wang 2, Heng Qiu 2, Chao Wang 2, Kai Chen 2, Renxiang Tan 6 7, Qile Gao 1, Jiake Xu 2

Publish date

2018 Jan


Description :

Empty ...